Skip to main content
Clinical Trials/NCT03600688
NCT03600688
Active, not recruiting
Not Applicable

Transcatheter Repair of Mitral Regurgitation With Cardioband System Post Market Study:A European Prospective, Multicenter Study to Assess Transcatheter Mitral Valve Repair With Edwards Cardioband System in Patients With Symptomatic MR

Edwards Lifesciences17 sites in 3 countries200 target enrollmentJune 6, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mitral Regurgitation
Sponsor
Edwards Lifesciences
Enrollment
200
Locations
17
Primary Endpoint
Procedure Success at discharge
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

To demonstrate reduction of MR with durable performance and im-provements in functional status

Detailed Description

MiBAND is a prospective, single arm, European post-market study to assess the safety and efficacy of the Edwards Cardioband system. Patients will be followed up at 30D, 6months, 1, 2 and 3 years.

Registry
clinicaltrials.gov
Start Date
June 6, 2018
End Date
December 31, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Edwards Lifesciences
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years;
  • MR (≥ 2+ by echocardiography);
  • Patient is eligible to receive the Edwards Cardioband Mitral System

Exclusion Criteria

  • Active bacterial endocarditis
  • Severe organic lesions with retracted chordae or congenital mal-formations with lack of valvular tissue
  • Heavily calcified annulus or leaflets
  • Patients in whom transesophageal echocardiography is contraindicated
  • Patients who cannot tolerate an anticoagulation/antiplatelet regimen
  • Patients with known severe reaction to contrast agents that cannot be adequately pre-medicated.
  • Pre-existing prosthetic heart valve or annuloplasty in the Mitral position
  • Life expectancy of less than twelve months
  • Patient is pregnant or lactating

Outcomes

Primary Outcomes

Procedure Success at discharge

Time Frame: Hospital discharge; approximately 2-8 days post-procedure

Reduction in Severity of Mitral Regurgitation at discharge

Secondary Outcomes

  • Procedure Success(30 days, 6months, 1, 2 and 3 years)
  • Major Adverse Events Rate(30 days, 6months, 1, 2 and 3 years)
  • Change in Quality Of Life-KCCQ(30 days, 6 months, 1, 2 and 3 years)
  • Change in Quality Of Life-EQ-5D-5L(30 days, 6 months, 1, 2 and 3 years)

Study Sites (17)

Loading locations...

Similar Trials